The accordance of the pathophysiology of esophageal motility disorders with the mechanism of action of PDE5 inhibitors raises the question of whether PDE5 inhibitors such as sildenafil are effective treatment options for esophageal motility disorders such as achalasia. This evidence concerns the gene PDE5A and Achalasia.